ACTELIS NETWORKS INC
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Condensed Consolidated Interim Financial Statements
NOTE 1 – GENERAL:
| a. | Actelis Networks, Inc. (hereafter -the Company) was established in 1998, under the laws of the state of Delaware. The Company has a wholly-owned subsidiary in Israel, Actelis Networks Israel Ltd. (hereafter – the Subsidiary). The Company is engaged in the design, development, manufacturing, and marketing of cyber hardened, hybrid fiber, networking solutions for IoT and Telecommunication governmental agencies and companies. The Company’s customers include governmental agencies, providers of telecommunication services, enterprises as well as resellers of the Company’s products. On May 12, 2022, the Company accepted a notification of effectiveness from the SEC, and on May 17, 2022, completed its IPO. The Company’s Common Stock is listed on the NASDAQ. |
| b. | The Company has incurred significant losses and negative cash flows from operations. Net loss was $ 1,860 and $1,986 for the Three months ended March 31, 2025, and March 31, 2024, respectively. During the Three months ended March 31, 2025, and March 31, 2024, the Company had negative cash flows from operations of $ 2,174 and $203, respectively. As of March 31, 2025, the Company’s accumulated deficit was $ 46 million. The Company has funded its operations to date through equity and debt financing and has cash on hand (including restricted cash equivalents) of $1.4 million and long-term restricted bank deposits of $91 and long term deposit of $85 as of March 31, 2025. The Company monitors its cash flow projections on a current basis and takes active measures to obtain the funding it requires to continue its operations. However, these cash flow projections are subject to various uncertainties concerning their fulfilment such as the ability to continue to increase revenues and gross margin and reduce its operating cost and expenses. If the Company is not successful in generating sufficient cash flow or completing additional financing, including debt financing, then it will need to execute a new cost reduction plan in addition to previous cost reduction plans that were executed so far. The Company’s transition to profitable operations is dependent on generating a level of revenues adequate to support its cost and expense structure. The Company expects to fund operations using cash on hand, through operational cash flows and raising additional equity and debt funds as well as improving its gross margin through better revenue mix and generating other efficiencies. There are no assurances, however, that the Company will be able to generate the revenue necessary to support its cost and expense structure or that it will be successful in obtaining the level of financing necessary for its operations. Management has evaluated the significance of these conditions and has determined that the Company does not have sufficient resources to meet its operating obligations for at least one year from the issuance date of these consolidated financial statements. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. These consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. |
NOTE 1 – GENERAL:(continued):
| c. | On October 7, 2023, Hamas terrorists initiated a series of terror attacks targeting both civilian and military sites in Southern and Central Israel, prompting a response from the Israel Defense Forces. Additionally, Hezbollah and the Houthi movement launched attacks on military and civilian locations in Israel, leading to further Israeli responses, including intensified air and ground operations in Lebanon. The Houthi movement also targeted international shipping lanes in the Red Sea. On April 14, 2024, and again on October 1, 2024, Iran carried out drone and missile strikes against Israel, to which Israel responded. The conflicts in both Lebanon as well as Gaza are in a state of cease fire under accords signed between the parties. Recently, the accord has been broken. However, the duration and intensity of the ongoing conflicts in Gaza, Northern Israel, Lebanon, and the broader region remain uncertain. As of the signing date, our operations and financial results have not been significantly impacted, though, as of May 13, 2025, two of our employees has been called to reserve duty in the Israel Defense Forces from time to time, which has not been materially affecting our operation. We do not anticipate any short-term material impact on our business performance due to the ongoing conflicts in the Gaza Strip, Lebanon, and the security situation in Israel. However, as this is an unpredictable event, its continuation or resolution could influence our expectations. We are closely monitoring political and military developments and assessing their potential impact on our operations, financial performance, and overall business condition. |
| d. | On August 25, 2023, the Company received a notification letter from the Nasdaq Staff indicating that we are not in compliance with Nasdaq Listing Rule 5550(b)(1) due to the company’s failure to meet the Minimum Shareholders’ Equity Requirement or any alternatives to such requirement. In order to maintain listing on the Nasdaq Capital Market, the company has submitted a plan of compliance addressing how we intended to regain compliance. The company had until February 21, 2024 to evidence compliance with the Minimum Shareholders’ Equity Requirement. On March 27, 2024, the Company received a delist determination letter (the “Delist Letter”) from the Staff advising the Company that the Staff had determined to delist the Company’s securities from Nasdaq due to its non-compliance with the Equity Rule unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel. Following the hearing, on June 10, 2024, the Panel granted the Company’s request for continued listing subject to the Company evidencing compliance with the Minimum Shareholders’ Equity Requirement by August 27, 2025. Additionally, on May 20, 2024, Nasdaq notified the Company that it was not in compliance with the minimum bid price requirements under Nasdaq Listing Rule 5550(a)(2), which requires the Company’s common stock to maintain a minimum bid price of $1.00 per share. On June 20, 2024, the Company received a letter from Nasdaq stating that, for 10 consecutive business days from June 5, 2024, to June 28, 2024, the closing bid price of its common stock had been at or above $1.00 per share. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq considers the prior bid price deficiency matter closed. |
NOTE 1 – GENERAL:(continued):
| e. | Recent changes in international trade policies and tariffs have significantly impacted imports and exports, leading to increased costs and disrupted supply chains. Geopolitical tensions and trade disputes can make our products more expensive for customers, reducing demand and attractiveness. The U.S. has recently implemented new tariffs, prompting other countries to impose or consider retaliatory tariffs. This uncertainty in trade policies, taxes, and regulations could negatively affect our business and operating results. Our products, manufactured in Israel and Taiwan, are imported to the U.S., and tariffs could increase the cost of inputs, equipment, materials, and components. These increased costs may lead to higher product prices, reducing demand and adversely impacting our revenue and financial results. |
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:
| a. | Basis of presentation |
The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with Article 10 of the Securities and Exchange Commission (“SEC”)’s Regulation S-X. As permitted under those rules, certain footnotes and other financial information that are normally required by generally accepted accounting principles in the United States (“U.S. GAAP”) can be condensed or omitted. These financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of its financial position as of and for the periods presented. These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2024. The results of operations for the three months ended March 31, 2025, are not necessarily indicative of results that could be expected for the 2025 fiscal year or any other interim period or for any other future year. All intercompany transactions and balances have been eliminated in consolidation.
| b. | Use of estimates in preparation of financial statements |
The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:(continued):
| c. | Segments |
Our Chief Executive Officer (CEO), as the Chief Operating Decision Maker (CODM), oversees the Company’s business activities as a single operating and reportable segment at the consolidated level. Accordingly, the CODM evaluates segment performance, allocates resources, and measures profit or loss based on consolidated net loss. Additionally, the CODM monitors and manages the Company’s operations by reviewing functional expenses—including cost of revenues, sales and marketing, research and development, and general and administrative expenses—at the consolidated level.
| d. | Fair value of financial instruments |
Fair value measurements are classified and disclosed in one of the following three categories:
Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 – Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The Company measured the fair value of the warrants liability it issued based on Level 3 inputs, and the warrants liability amounted to $0 as March 31, 2025 and December 31, 2024.
As of March 31, 2025, and December 31, 2024, the fair values of the Company’s cash and cash equivalents, restricted cash equivalents, trade receivables, trade payables, long-term loan, short term loans, restricted bank deposits, Severance pay fund and other current assets approximated the carrying values presented in the Company’s condensed consolidated balance sheets because of their nature.
| e. | Concentration of risk |
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash equivalents, and trade receivables. Cash and cash equivalents and restricted cash equivalents are placed with banks and financial institutions in the United States and Israel.
Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.
The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:(continued):
Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the condensed consolidated financial statements. Management makes judgments as to its ability to collect outstanding accounts receivable and provides allowances for the applicable portion of accounts receivable when collection becomes doubtful.
The Company estimates CECL (Current Expected Credit Losses) on trade receivables at inception for estimated losses resulting from the inability of the Company’s customers to make required payments, based on estimated current expected credit losses. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering historical information, current market conditions and reasonable and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations.
The Company has customers balances representing 10% or more of Trade receivables as follows:
| 1) | Customer A represented 49% and 39 % of the Company Trade receivables balance as of March 31, 2025, and December 31, 2024, respectively. |
The Company does not see any credit risk regarding the major trade receivable balance.
| f. | New Accounting Pronouncements |
Accounting Pronouncements effective in future periods
In December 2023, the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures. The ASU improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for the Company for annual periods beginning after December 15, 2025. The Company is evaluating the potential impact of this guidance on its consolidated financial statements. The amendments in this Update should be applied on a prospective basis. Retrospective application is permitted.
In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure (Subtopic 220-40): Disaggregation of Income Statement Expense and ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU improves the disclosures about a public business entity’s expenses and provides more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, general and administrative, and research and development). The ASU is effective for annual reporting period beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the potential impact of this guidance on its consolidated financial statement disclosures.
NOTE 3 – INVENTORIES:
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| Raw materials | 1,577 | 1,521 |
| Finished goods | 931 | 915 |
| 2,508 | 2,436 |
Inventory write-downs amounted to $5 and$ 0 during the three months ended March 31, 2025, and March 31, 2024, respectively. Inventories write-downs are recorded in cost of revenues.
NOTE 4 – LOANS:
| a. | As a result of the COVID pandemic, the US and Israeli governments offered different programs of financial aid. The Company participated in the following programs: |
On July 1, 2020, the Company received Economic Injury Disaster Loan (the “EIDL Loan”) from an American Bank under the Small Business Administration COVID19 Program in the total of $150. The loan matures in June, 2050 and bears interest of 3.75% per annum, payable monthly commencing on January 1, 2023, unless forgiven per program regulations. As of March 31, 2025, the total loan balance outstanding was $150.
| b. | In February 2024, the Company performed a partial early repayment of Migdalor Loan in the amount of 2 million NIS (approximately $550). During April and May 2024, the Company made an additional partial early repayment of Migdalor loan in the amount of 10.9 million NIS (approximately $2,933). In May 2024, the Company signed an amendment to the agreement with Migdalor, pursuant to which the remaining $470 of the one-time interest payment which was originally due in January 2024 to Migdalor will be paid in 12 equal monthly payments bearing 9.6% interest from February 2024 till February 2025. |
In addition, the Company is obligated to issue Migdalor warrants to acquire common stock for up to $150 subject to the terms of amendment.
In July 2024, the company repaid the remaining loan balance to Migdalor, totaling 1.16 million ILS (approximately 0.3$ million )
As of March 31, 2025, the total outstanding of the one-time interest payment was approximately $54 thousand.
| c. | As of March 31, 2025, the Subsidiary used $0.4 million of the credit line entered into on January 15, 2024. |
NOTE 5 – COMMITMENTS AND CONTINGENCIES:
The Company is obligated to repay certain research and development grants received from the Government of Israel in the form of a royalty rate on future sales of products derived from the funded research and development activities. The aggregate amount of royalties to be paid is determined based on 100% of the total grants received for qualified projects plus interest. The Company may be required to pay royalties based on previous years funding in periods after March 31, 2025, for the future sale of product that includes technology developed and funded with these research and development grants received to date.
In October 2024, the company entered into a payment plan with the Israel Innovation Authority (“IIA”) to settle the outstanding amount as of the previous year. According to the agreement, the IIA agreed to offset a delayed payment of approximately $50 from the total outstanding amount. The company committed to making an immediate payment of $190 and to spread the remaining balance over two years, with quarterly installments of approximately $106 starting from October 2024. The outstanding debt will continue to accrue interest and linkage differences in accordance with legal requirements until fully settled. Additionally, the company is required to report and pay ongoing royalties starting from the first half of 2024.
During the three months ended March 31, 2025, and December 31, 2024, the company repaid $236 and $400 respectively.
As of March 31, 2025, the Company had received approximately $14,300 (approximately $15,830 including interest) and repaid approximately $10,857 in such grants.
As of March 31, 2025, and December 31, 2024, the Company had a liability to pay royalties in the amount of approximately $624 thousands and $839 thousands respectively.
NOTE 6 – SHAREHOLDERS’ EQUITY:
| a. | As of March 31, 2025 total of 10,690 common stock are held by the company as treasury shares. |
| b. | Total outstanding warrants as of March 31, 2025, are as follow: |
| Number of warrants | Exercise price | Period left in years | |
|---|---|---|---|
| Warrants May 2023 | 66,127 | $4.625 | 3.9 |
| Warrants December 2023 | 1,360,170 | $1.18 - $1.47 | 4.5 |
| Warrants June 2024 | 1,069,647 | $2 - $3.43 | 5.0 |
| Warrants July 2024 | 2,069,317 | $2.5 - $1.75 | 1.75 |
| Other | 36,942 | $10.27 - $50 | 1.50 - 2.4 |
| Outstanding as of March 31, 2025 | 4,602,203 | ||
| c. | At the Market Offering Agreement: |
On September 18, 2024, the Company entered into At the Market Offering Agreement (the “ATM Agreement”), with H.C. Wainwright & Co. (“Wainwright”), as sales agent, pursuant to which the Company may issue and sell shares of its common stock, from time to time, through Wainwright.
Under the ATM Agreement, Wainwright may sell shares in transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act, as amended, or in any other method permitted by law, including in privately negotiated transactions.
The Company or Wainwright may suspend or terminate the ATM Agreement upon notice to the other party and subject to other conditions.
The Company will pay Wainwright a commission of 3.0% of the gross sales price of any common stock sold under the ATM Agreement and has agreed to provide Wainwright with customary indemnification and contribution rights. The Company will also reimburse Wainwright for certain specified expenses.
During the first quarter of 2025, the company issued and sold 1,394,934 shares of common stock for gross proceeds of approximately $1,750 thousand. Total cost related to the offering is approximately $170.
NOTE 6 – SHAREHOLDERS’ EQUITY: (continued):
| d. | Share-based compensation: |
| 1) | A summary of the Company’s share options, granted to employees, directors, under option plans is as follows: |
| Number of options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life | |
|---|---|---|---|
| Outstanding – January 1, 2025 | 62,678 | 4.38 | 3.4 |
| Granted | - | - | - |
| Exercised | - | - | - |
| Forfeited | (1,248) | 5.21 | - |
| Outstanding – March 31, 2025 | 61,430 | 4.36 | 2.85 |
| Exercisable – March 31, 2025 | 58,618 | 3.73 | 2.62 |
The majority of the Share-based compensation expenses included in the Condensed consolidated statements of comprehensive loss under General and Administrative.
As of March 31, 2025, the unrecognized compensation costs related to those unvested stock options are $11, which are expected to be recognized over a weighted-average period of 1 years.
| 2) | A summary of the Company’s RSUs, granted to employees, directors, under option plans is as follows: |
| Number of RSUs | Weighted- Average Grant Date Fair Value | |
|---|---|---|
| RSUs outstanding at the beginning of the year | 36,254 | 12.38 |
| Granted during the period | - | - |
| Vested during the period | (1,665) | 5.28 |
| Forfeited during the period | - | - |
| Outstanding as of March 31, 2025 | 34,589 | 12.72 |
The majority of the RSUs expenses included in the Condensed consolidated statements of comprehensive loss under General and Administrative.
As of March 31, 2025, the unrecognized compensation cost related to unvested RSUs totaled to approximately $331 and is expected to be expensed over a weighted-average recognition period of approximately 1.7 years.
NOTE 7 – BASIC AND DILUTED LOSS PER SHARE:
Basic net loss per share is computed using the weighted average number of shares of common stock and pre-funded warrants and fully vested RSUs outstanding during the period, net of treasury shares. In computing diluted loss per share, basic loss per share is adjusted to take into account the potential dilution that could occur upon the exercise of options and RSUs granted under employee stock compensation plans, and the exercise of warrants using the treasury stock method.
Diluted loss per share excludes 4,602,203 shares underlying outstanding warrants,61,430 shares underlying outstanding options, and 34,589 shares underlying outstanding RSUs for the three months ended March 31, 2025, because the effect of their inclusion in the computation would be antidilutive.
Diluted loss per share excludes 2,462,759 shares underlying outstanding warrants,87,041 shares underlying outstanding options, and 68,648 shares underlying outstanding RSUs for the three months ended March 31, 2024, because the effect of their inclusion in the computation would be antidilutive.
The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders:
| Three months ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Numerator: | ||
| Net loss | $(1,860) | $(1,986) |
| Denominator: | ||
| Common shares outstanding used in computing net loss per share attributable to common shareholders | 8,520,110 | 3,008,641 |
| Pre-Funded warrants to purchase common shares | - | 970,187 |
| Weighted average number of shares used in computing basic and diluted net loss per share attributable to common shareholders | 8,520,110 | 3,978,828 |
| Net loss per share attributable to common shareholders – basic and diluted | $(0.22) | $(0.50) |
NOTE 8 – ENTITY WIDE INFORMATION AND DISAGGREGATED REVENUES:
The Company operates asone operating segment (developing and marketing access broadband equipment for copper and fiber networks).
| a. | Geographic information: |
Following is a summary of revenues by geographic areas. Revenues attributed to geographic areas, based on the location of the end customers:
| Three months ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| North America | 477 | $389 |
| Europe, the Middle East and Africa | 230 | 335 |
| Asia Pacific | 14 | 2 |
| $721 | $726 | |
| b. | Revenues from contract liability: |
| Three months ended, March 31, 2025 | Three months ended, March 31, 2024 | |
|---|---|---|
| Opening balance | 339 | 460 |
| Revenue recognized that was included in the contract liability balance at the beginning of the year | (68) | (242) |
| Additions | 79 | 155 |
| Ending balance | 350 | 373 |
As of March 31, 2025, the aggregate amount of the transaction price allocated to the remaining performance obligation is $350, and the Company will recognize this revenue over the next 12-18 months.
| c. | Customers representing 10% or more of net revenues and the amount of revenues recognized are as follows: |
| % | Revenues | |
|---|---|---|
| U.S. dollars in thousands | ||
| Customer A | 19% | 136 |
| % | Revenues | |
|---|---|---|
| U.S. dollars in thousands | ||
| Customer A | 5% | 35 |
The majority of the Company’s revenues are recognized at a point in time.
NOTE 9 - SUBSEQUENT EVENT:
On May 12, 2025, Nasdaq notified the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2), which requires common stock to maintain a minimum bid price of $1.00 per share. The notification letter has no immediate effect on the listing or trading of the common stock on Nasdaq and the common stock will continue to trade on Nasdaq under the symbol “ASNS”.
The Notification Letter provides that the Company has 180 calendar days, or until November 10, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.